CoChat

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease

Gal, S., Fridkin, M., Amit, T., Zheng, H., Youdim, M. B. H. · 2006 · Parkinson’s Disease and Related Disorders

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Iron and monoamine oxidase activity are increased in brain of Parkinson's disease (PD). They are associated with autoxidation and oxidative deamination of dopamine by MAO resulting in the generation of reactive oxygen species and the onset of oxidative stress to induce neurodegeneration. Iron chelators (desferal, Vk-28 and clioquinol) but not copper chelators have been shown to be neuroprotective in the 6-hydroxydoapmine and MPTP models of Parkinson's disease (PD), as are monoamine oxidase B inhibitors such as selegiline and rasagiline. These findings prompted the development of multifunctional anti PD drugs possessing iron chelating phamacophore of VK-28 and the propargylamine MAO inhibitory activity of rasagiline. M30 is a potent iron chelator, radical scavenger and brain selective irreversible MAO-A and B inhibitor, with little inhibition of peripheral MAO. It has neuroprotective activity in in vitro and in vivo models of PD and unlike selective MAO-B inhibitors it increases brain dopamine, serotonin and noradrenaline. These findings indicate beside its anti PD action, it may also possess antidepressant activity, similar to selective MAO-A and nonselective MAO inhibitors. These properties make it an ideal anti PD drug for which it is being developed.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-211-45295-0_68

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Research works printed but not linked: 1

  1. Foley F, Gerlach M, Youdim MBH, Riederer P (2000) MAO-B inhibitors: multiple roles in the therapy of neurodegenerative diseases. PARD 6: 25–47

Metadata

Authors
Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H.
Affiliations
  • Technion – Israel Institute of Technology (IL)
  • Weizmann Institute of Science (IL)
Venue
Parkinson’s Disease and Related Disorders
Published
2006
Issue
70
Pages
447-456
OpenAlex
W2179417997
Cited by
58
References
65
Citations by year
2024: 4 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 5 · 2012: 5
FWCI
6.61
Type
book chapter
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Springer eBooks (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
M30, Parkinson's disease, iron chelation, monoamine oxidase inhibition, monoamine oxidase A, monoamine oxidase B, neuroprotection, oxidative stress, dopamine autoxidation, reactive oxygen species, antidepressant effects, propargylamines, 6-hydroxydopamine model, MPTP model, dopamine, serotonin, norepinephrine
MeSH terms
Animals, Brain, Dopamine, Humans, Hydroxyquinolines, Iron Chelating Agents, Monoamine Oxidase Inhibitors, Synaptic Transmission, Parkinson Disease, Dopamine Agents, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease. https://app.cochat.ai/papers/10.1007/978-3-211-45295-0_68
The paper
Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H. (2006). M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease. Parkinson’s Disease and Related Disorders. https://doi.org/10.1007/978-3-211-45295-0_68

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.